Category: Press Releases

SAN FRANCISCO, July 13, 2023 (GLOBE NEWSWIRE) — OKX, a leading Web3 technology company, has issued updates for July 13, 2023.

OKX Wallet integrates into Nexus Mutual

OKX is proud to announce that Nexus Mutual has successfully integrated the OKX Wallet into their dApp.

Nexus Mutual is a decentralized insurance protocol built on the Ethereum blockchain that allows its members to join and share risk for DeFi. Nexus Mutual gives its members the ability to buy coverage that protects against different types of risk. It also underwrites risk, assesses claims, and creates risk management businesses.

The Nexus Mutual platform is run entirely by its members who decide which claims are valid and have their decisions recorded and enforced by smart contracts. Claim payments are enforced by token-driven economic incentives, eliminating the need to place trust in an insurance company.

For further information, please contact:
Media@okx.com

ENDS

About OKX

A leading global technology company driving the future of Web3, OKX provides a comprehensive suite of products to meet the needs of beginners and experts alike, including the OKX Wallet, NFT Marketplace and DEX.

OKX partners with a number of the world’s top brands and athletes, including: English Premier League champions Manchester City F.C., McLaren Formula 1, The Tribeca Festival, Olympian Scotty James, and F1 driver Daniel Ricciardo.

As a leader building innovative technology products, OKX believes in challenging the status quo. The company recently launched a global brand campaign entitled, The System Needs a Rewrite, which advocates for a new paradigm led by Web3 self-managed technology to replace existing centralized systems.

To learn more about OKX, download our app or visit: okx.com

Disclaimer

The information displayed is strictly for education and informational purposes only. It does not constitute and shall not be considered as an offer, solicitation or recommendation, to deal in any products (including any NFT or otherwise), or as financial or investment advice. Both OKX Web3 Wallet and OKX NFT Marketplace are subject to separate terms of service at www.okx.com.

GlobeNewswire Distribution ID 8874169

New York, July 13, 2023 (GLOBE NEWSWIRE) —  CertiK is proud to announce that its co-founder, Ronghui Gu, who is also Tang Family Assistant Professor of Computer Science at Columbia University, won the highly regarded 2022 VMware Systems Research Award.

VMware is a global leader in cloud infrastructure and virtualization technology. Established by VMware’s academic sector, the Systems Research Award aims to acknowledge and support promising emerging research in computer science systems. It shines a spotlight on groundbreaking research that has the potential to significantly advance the field of computer science.

Professor Gu is recognized for his fundamental contributions to the theory of systems verification. His work, translating theoretical results into real-world applications for creating bug-free and secure system software, has found novel applications.

Professor Gu’s most distinguished work is his Ph.D. thesis conducted at Yale University. This pioneering work involved the intricate task of certifying the CertiKOS operating system kernel, a complex endeavor encompassing everything from compilers to the fundamental building blocks of the operating system.

Gu’s advisor, and also co-founder at CertiK, Professor Zhong Shao says, “Certifying an operating system is a huge task, involving models of many components ranging from threads and processes to physical and virtual memory management. Ronghui was a main driver to make the CertiKOS vision become a reality: he addressed the complexity of concurrency, and he got the proofs done for a realistic system.”

Professor Greg Morrisett, Dean and Vice-Provost of Cornell Tech, says, “I think CertikOS is a tremendous leap forward, not so much in the artifact itself, but rather in the methodology used for constructing the proofs (though the artifact is also cool).”

“Ronghui’s work represents an important data point in the evolution of formal verification technique,” said VMware Fellow Pratap Subrahmanyam, as quoted by VMWare. “Making otherwise esoteric technologies accessible in practical settings is one reason we value Ronghui’s research.” VMware Fellow Christos Karamanolis added “Ronghui’s depth, breadth, and focus on the advancement of formal methods – including both core platforms and emerging areas such as Quantum Computing – is remarkable and representative of the kind of systems research focus we value in making this award.”

Reflecting his originality, potential for future impact, and the significance of his findings, the VMware University Research Fund will provide a grant of $125,000 to Columbia University in support of Professor Gu’s continuing research.

In 2018, Professor Gu and Professor Zhong Shao, Chair of Yale University’s Department of Computer Science, co-founded CertiK, a leading provider of blockchain security solutions. Leveraging advanced formal verification, AI auditing technologies, and expert manual checks, CertiK monitors the security of blockchain protocols and smart contracts.

The recognition of Professor Gu by the VMware Systems Research Award underscores the advanced level of sophistication that computer science academia has brought to the Web3 arena. Previous recipients of this esteemed award include professors of computer science at Stanford, MIT, Purdue, and Carnegie Mellon University.

About CertiK

CertiK is a pioneer in blockchain security, leveraging best-in-class technology to protect and monitor blockchain protocols and smart contracts. Founded in 2018 by professors from Yale University and Columbia University, CertiK’s mission is to secure the Web3 world. CertiK applies cutting-edge innovations from academia to enterprise, enabling mission-critical applications to scale with safety and correctness.

One of the fastest-growing and most trusted companies in blockchain security, CertiK is a true market leader. To date, CertiK has worked with nearly 4,000 enterprise clients, secured over $360 billion worth of digital assets, and has detected nearly 70,000 vulnerabilities in blockchain code. Clients include leading projects such as Aave, Polygon, Binance Smart Chain, Yearn Finance, and Chiliz.

Hari Govindarajan
PR & Comms Specialist, Luna PR
hari@lunapr.io

GlobeNewswire Distribution ID 1000829843

NEW YORK, July 13, 2023 (GLOBE NEWSWIRE) — Citeline, a global leader in clinical trial intelligence, has announced a strategic partnership with Clinrol, a clinical trial recruitment company, to expand and enhance patient recruitment for upcoming clinical trials across the Asia-Pacific (APAC) region. Clinrol is currently recruiting research participants in Australia for clinical trials in diabetes, cancer, dermatitis and other therapeutic areas.

The partnership will combine Clinrol’s deep understanding of the Asia-Pacific clinical research and advertising landscape with Citeline’s comprehensive clinical trial intelligence platform to efficiently identify and engage with potential patients while preserving privacy. Clinrol’s long expertise in clinical trial recruitment and data-driven marketing will be used to create and implement targeted patient recruitment campaigns across multiple channels.

“Enrolling patients in clinical trials is a well-documented challenge. The difficulty of patient recruitment has been further intensified by the increasing complexity and requirements of protocols in recent studies. We are excited to appoint Clinrol as a strategic APAC partner and to further improve and expand our patient recruitment capabilities in the Asia Pacific region,” said Dave Laky, General Manager, Clinical & Regulatory at Citeline. “With their extensive experience in the Asia-Pacific market, we are thrilled to be working closely alongside the Clinrol team to innovate in this critical area for patients and pharma, ultimately accelerating the pace of clinical trials in the region and improving patient outcomes.”

Citeline’s suite of complementary pharmaceutical business intelligence tools and solutions is widely recognized as the most comprehensive and up-to-date resource for clinical trial information, with data covering over 50 therapeutic areas and more than 200 countries. By combining this data and Citeline Connect’s Global Patient Recruitment Collective with Clinrol’s expertise in marketing, the partnership aims to improve patient recruitment rates and ultimately reduce the time and cost associated with clinical trial recruitment.

“With our understanding of the APAC clinical research landscape coupled with data-driven marketing, we are confident that we can help accelerate the pace of clinical research and make a real difference in people’s lives,” said Arjun Bhat, Co-Founder and Chief Executive Officer of Clinrol. “Patient enrollment is one of the primary reasons a clinical trial fails, and at least 80% of pharmaceutical trials do not meet enrollment deadlines. Approximately $1 million AUD of losses is experienced each day a trial is delayed. We are thrilled to partner with Citeline to speed up the pace of recruitment and help bring life-changing therapies to patients in need.”

For more information on the Citeline Connect patient referral network, visit https://pages.pharmaintelligence.informa.com/Partner-Connect-100-Sponsor.

About Clinrol

Clinrol was established in 2020, specializing in data-driven patient recruitment and management of clinical trials. Using state-of-the-art marketing strategies, technology and expertise, Clinrol more effectively finds, pre-screens, recruits and manages patients while maintaining strict ethical and privacy principles for clinical trials globally.

About Citeline

Citeline, a Norstella company, powers a full suite of complementary business intelligence offerings to meet the evolving needs of life science professionals to accelerate the connection of treatments to patients and patients to treatments. These patient-focused solutions and services deliver and analyze data used to drive clinical, commercial, and regulatory-related decisions and create real-world opportunities for growth.

Citeline’s global teams of analysts, journalists and consultants keep their fingers on the pulse of the pharmaceutical, biomedical and medtech industries, covering it all with expert insights: key diseases, clinical trials, drug R&D and approvals, market forecasts and more. For more information on one of the world’s most trusted health science partners, visit Citeline.

For more information about Clinrol and Citeline, please visit their respective websites.

Media Contact:
Clinrol
Ram Bhat | Chief Marketing Officer
+61 472 705 327 | ram@clinrol.com

Citeline
Diffusion PR for Citeline
citeline@diffusionpr.com
(213) 318-4500

GlobeNewswire Distribution ID 8873419